Litcius/Paper detail

First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with 177Lutetium – Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial, on behalf of the ENDOCAN RENATEN network and GTE

Éric Baudin, T. Walter, C. Docao, M. Haissaguerre, Julien Hadoux, D. Taieb, C. Ansquer, L. Dierickx, L. De Mestier, E. Deshayes, E. Quak, S. Foulon

2022Annales d Endocrinologie10 citationsDOI

Topics & Concepts

Radionuclide therapyPeptide receptorMedicineNeuroendocrine tumorsOncologyInternal medicineRandomized controlled trialNuclear medicineReceptorNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments
First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with 177Lutetium – Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial, on behalf of the ENDOCAN RENATEN network and GTE | Litcius